Since these TNFAIP8-induced cellular events all have significance in early liver disease and progression to HCC, targeting TNFAIP8 activity in early liver diseases may provide therapeutic benefit for specific patient populations. Here, TNFAIP8 is linked to hepatocellular carcinoma.